Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FT500 Monotherapy and Combination in Advanced Solid Tumors
NCT03841110Phase 1Completed
- Sponsor
- Fate Therapeutics
- Start
- Feb 2019
- Primary completion
- Nov 2022
- Modality
- Patient-derived iPSCs, Lymphokine-Activated Killer Cells, Allogeneic iPSCs
- Countries
- 1
01
Overview
Phase 1, open-label trial of FT500 in solid tumor (advanced stage) and lymphoma (3 arms), sponsored by Fate Therapeutics. Primary endpoint: Incidence of Dose Limiting Toxicities at Day 29. Started Feb 2019; status: completed.
02
Drugs
FT500
03
Conditions
solid tumor (advanced stage)lymphoma
Beyond the preview
Go deeper on NCT03841110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03841110.